ClinicalTrials.gg
CompletedNCT01724021Updated Jan 23, 2018Results posted

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

A Phase 3 interventional study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) and Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP) in Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 246 sites in 32 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
743
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse — 20 open to participants now, 38 under way, 4 of them phase 3. Rituximab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
4th of 211
743 · median 46
Started
2012
with 6 others
Phase 3
30 of 218
2 open now
Registered
127th of 218
by date
Lead sponsor
7 of 218
Hoffmann-La Roche

Among the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, this one is the 4th largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2012, is one of 30 in phase 3, and was the 127th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

20 of the 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 218 studies testing rituximab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma or CD20+ follicular non-Hodgkin's lymphoma. In Arm A, participants will receive MabThera/Rituxan 375 mg/m2 intravenously (IV) on Day 1 of Cycle 1 and MabThera/Rituxan 1400 mg subcutaneously (SC) on Day 1 of Cycles 2-4, followed by MabThera/Rituxan IV in Cycles 5-8. Participants in Arm B will receive MabThera/Rituxan IV in Cycles 1-4 and SC in Cycles 5-8. All participants will receive 6-8 cycles of standard chemotherapy (according to local country practice) with 8 cycles of MabThera/Rituxan. Anticipated time on study treatment is up to 24 weeks.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants , >/= 18 and \</= 80 years of age
  • confirmed, previously untreated CD20+ diffuse large B-cell lymphoma (DLBCL) or CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2, or 3a, according to World Health Organization (WHO) classification
  • An International Prognostic Index (IPI) score of 1-4 or IPI score of 0 with bulky disease, defined as one lesion >/= 7.5 cm, or Follicular Lymphoma International Prognostic Index (FLIPI; low, intermediate or high risk)
  • At least one bi-dimensionally defined as >/=1.5 cm in its largest dimension on CT scan
  • (ECOG) performance status \</= 3

Exclusion criteria

Exclusion Criteria:

  • Transformed lymphoma or follicular lymphoma IIIB
  • Primary central nervous system (CNS) lymphoma, histologic evidence of transformation to Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, primary cutaneous DLBCL, or primary DLBCL of the testis
  • History of other that could affect compliance with the protocol or interpretation of the results; this includes a malignancy that has been treated but not with curative intent, unless the malignancy has been in remission for >/= 5 years prior to enrolment; participants with a history of curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the cervix are eligible
  • Prior therapy for DLBCL or NHL, with the exception of nodal or local irradiation
  • Prior treatment with cytotoxic drugs (with the exclusion of intrathecal methotrexate for CNS prophylaxis in DLBCL) or rituximab for another condition, or prior use of an anti-CD20 drug
  • Prior use of monoclonal antibody within 3 months prior to randomization
  • Chemotherapy or other therapy within 28 days prior to randomization
  • Ongoing use > 30 mg/day prednisolone or equivalent
  • Inadequate renal. hematologic or hepatic function
  • Active and/or severe infection or any major episode of infection within 4 weeks prior to randomization
  • Active virus or active virus infection
  • History of human immunodeficiency () seropositive status
  • A positive pregnancy test in women of
  • of less than 6 months
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
743 participants (actual)

Study arms

  • Experimental
    Arm A

    Participants in Arm A received one cycle of rituximab 375 mg/m\^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m\^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.

    Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) · Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP) · Drug: Bendamustine · Drug: Rituximab

  • Experimental
    Arm B

    Participants in Arm B received four cycles of rituximab 375 mg/m\^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.

    Drug: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) · Drug: Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP) · Drug: Bendamustine · Drug: Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6

    Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6.

    Time frame: Cycle 6 (Up to 24 weeks)

  2. Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8

    Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8.

    Time frame: Cycle 8 (Up to 32 weeks)

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: Randomization of first participant to clinical cutoff date (Up to 4 years)

  2. Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])

    Administration time was defined as the time from start to end of the SC injection or from start to end of the IV infusion

    Time frame: Cycle 1-4, Cycle 5-8 for both SC and IV (Up to 32 weeks)

  3. Cancer Therapy Satisfaction Questionnaire (CTSQ) Score

    CTSQ is a validated 16-item questionnaire that measures three domains related to participants' satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

    Time frame: During Cycle 4, 8 of treatment (Up to 32 weeks)

  4. Rituximab Administration Satisfaction Questionnaire (RASQ) Score

    The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

    Time frame: During Cycle 4, 8 of treatment (Up to 32 weeks)

  5. Complete Response (CR) Rate

    CR rate was assessed according to the International Working Group (IWG) Response Criteria (CHESON ET AL. 1999) and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment. Tumor assessments were based on computed tomography (CT) scans with contrast of the neck, chest, and abdomen (if detectable by these techniques) or other diagnostic means, if applicable. Other methods (e.g., MRI) were acceptable for participants in whom contrast CT scans were contraindicated. Due to the limited availability of FDG-PET scanners, an FDG-PET scan was not mandated in the study.

    Time frame: 28 days (± 3 days) after Day 1 of the last dose of induction treatment

  6. Event-free Survival (EFS)

    EFS was defined as the time from randomization to first occurrence of progression or relapse according to IWG response criteria. IWG criteria is defined using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; partial response (PR): At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; stable disease (SD): participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (PD); PD: Lymph nodes considered abnormal if the long axis is more than 1.5 centimeter (cm) regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes less than or equal to (\<=) 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.

    Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

  7. Disease-free Survival (DFS)

    DFS was defined as the period from the data of the initial CR/CRu until the date of relapse or death from any cause, whichever occurred first.

    Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

  8. Progression-free Survival (PFS)

    PFS was defined as the time from randomization to the first occurrence of progression or relapse, according to the IWG response criteria. IWG criteria is defined criteria using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; PR: At least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses; SD: participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD; PD: Lymph nodes considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes \<= 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.

    Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

  9. Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause.

    Time frame: From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)

  10. Percentage of Participants With Anti-Rituximab Antibodies Over Time

    Time frame: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)

  11. Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time

    Time frame: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)

  12. Summary of Observed Serum Rituximab Concentration

    Time frame: Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)

07

Results

Posted Aug 29, 2016

Participant flow

Participant flow — Overall Study
MilestoneArm AArm B
Started371369
Completed244236
Not completed127133
Withdrew: Adverse event116
Withdrew: Death4658
Withdrew: Participant request/ withdrew consent1814
Withdrew: Lost to follow-up1515
Withdrew: Reason not specified3639
Withdrew: Missing11

Outcome measures

PrimaryPercentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6

Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing cycle 6.

Time frame:
Cycle 6 (Up to 24 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 6
percentage of participantsArm AArm B
Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 679.1 (74.2 to 83.5)80.6 (75.7 to 84.8)
PrimaryPercentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8

Participants who preferred rituximab SC over rituximab IV, along with the corresponding 95% confidence interval (CI), were estimated using the patient preference questionnaire (PPQ) after completing Cycle 8.

Time frame:
Cycle 8 (Up to 32 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 8
percentage of participantsArm AArm B
Percentage of Participants Indicating a Preference for Rituximab Subcutaneous (SC) Over Rituximab Intravenously (IV) at Cycle 877.1 (71.9 to 81.8)84.2 (79.6 to 88.2)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
Randomization of first participant to clinical cutoff date (Up to 4 years)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
participantsArm AArm B
Number of Participants With Treatment Emergent Adverse Events (AEs)352347
SecondaryTime Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])

Administration time was defined as the time from start to end of the SC injection or from start to end of the IV infusion

Time frame:
Cycle 1-4, Cycle 5-8 for both SC and IV (Up to 32 weeks)
Reported as:
Median · minutes
Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])
minutesRituximab Intravenous (IV)Rituximab Subcutaneous (SC)
Time Required for Rituximab Administration (Subcutaneous [SC] or Intravenous [IV])840 (0 to 3967.0)22 (0 to 1242.0)
SecondaryCancer Therapy Satisfaction Questionnaire (CTSQ) Score

CTSQ is a validated 16-item questionnaire that measures three domains related to participants' satisfaction with cancer therapy. These include expectations of therapy, feelings about side effects, and satisfaction with therapy. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

Time frame:
During Cycle 4, 8 of treatment (Up to 32 weeks)
Reported as:
Mean · units on a scale
Cancer Therapy Satisfaction Questionnaire (CTSQ) Score
units on a scaleRituximab Intravenous (IV)Rituximab Subcutaneous (SC)
Expectations of therapy domain80.88 ± 18.31582.07 ± 17.817
Feelings about side effects domain60.63 ± 22.31661.64 ± 22.324
Satisfaction with therapy domain84.59 ± 12.21885.42 ± 11.259
SecondaryRituximab Administration Satisfaction Questionnaire (RASQ) Score

The RASQ is a 20-item questionnaire that measures five domains related to the impact of treatment administration. These include physical impact, psychological impact, impact on activities of daily living (ADLs), convenience, and satisfaction. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants.

Time frame:
During Cycle 4, 8 of treatment (Up to 32 weeks)
Reported as:
Mean · units on a scale
Rituximab Administration Satisfaction Questionnaire (RASQ) Score
units on a scaleRituximab Intravenous (IV)Rituximab Subcutaneous (SC)
Physical impact domain82.14 ± 15.62982.08 ± 15.882
Psychological Impact domain77.73 ± 16.37784.00 ± 14.358
Impact on activitiesf daily living59.49 ± 22.23381.86 ± 15.844
Convenience domain59.05 ± 20.75781.05 ± 13.088
Satisfaction domain74.88 ± 19.34987.26 ± 14.972
SecondaryComplete Response (CR) Rate

CR rate was assessed according to the International Working Group (IWG) Response Criteria (CHESON ET AL. 1999) and included CR and CR unconfirmed (CRu). CR was defined as complete disappearance of all clinical and radiographic evidence of disease and disease-related symptoms, regression of lymph nodes to normal size, absence of splenomegaly, and absence of bone marrow involvement. CRu was defined as disappearance of clinical and radiographic evidence of disease and absence of splenomegaly, with regression of lymph nodes by \> 75 % but still \>1.5 cm in size, and indeterminate bone marrow assessment. Tumor assessments were based on computed tomography (CT) scans with contrast of the neck, chest, and abdomen (if detectable by these techniques) or other diagnostic means, if applicable. Other methods (e.g., MRI) were acceptable for participants in whom contrast CT scans were contraindicated. Due to the limited availability of FDG-PET scanners, an FDG-PET scan was not mandated in the study.

Time frame:
28 days (± 3 days) after Day 1 of the last dose of induction treatment
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsArm AArm B
Complete Response (CR) Rate49.2 (43.5 to 54.9)52.7 (47.0 to 58.3)
SecondaryEvent-free Survival (EFS)

EFS was defined as the time from randomization to first occurrence of progression or relapse according to IWG response criteria. IWG criteria is defined using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; partial response (PR): At least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses; stable disease (SD): participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for progressive disease (PD); PD: Lymph nodes considered abnormal if the long axis is more than 1.5 centimeter (cm) regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes less than or equal to (\<=) 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.

Time frame:
From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Reported as:
Median · months
Event-free Survival (EFS)
monthsArm AArm B
Event-free Survival (EFS)NA (NA to NA)NA (NA to NA)
SecondaryDisease-free Survival (DFS)

DFS was defined as the period from the data of the initial CR/CRu until the date of relapse or death from any cause, whichever occurred first.

Time frame:
From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Reported as:
Median · months
Disease-free Survival (DFS)
monthsArm AArm B
Disease-free Survival (DFS)NA (NA to NA)NA (NA to NA)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from randomization to the first occurrence of progression or relapse, according to the IWG response criteria. IWG criteria is defined criteria using the following response categories: CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy; PR: At least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses; SD: participants fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD; PD: Lymph nodes considered abnormal if the long axis is more than 1.5 cm regardless of the short axis. Lymph node has a long axis of 1.1 to 1.5 cm, it is considered abnormal if its short axis is more than 1.0. Lymph nodes \<= 1.0 × \<= 1.0 cm would not be considered as abnormal for PD.

Time frame:
From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm AArm B
Progression-free Survival (PFS)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death from any cause.

Time frame:
From the time of randomization until disease progression or 24 months post treatment follow up or which ever occur first (Up to 4 years)
Reported as:
Median · months
Overall Survival (OS)
monthsArm AArm B
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryPercentage of Participants With Anti-Rituximab Antibodies Over Time
Time frame:
Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Rituximab Antibodies Over Time
percentage of participantsArm AArm B
Cycle 12.03.0
Cycle 22.12.2
Cycle 30.30.9
Cycle 400.3
Interim staging00
Cycle 500
Cycle 600
Cycle 700
Cycle 800
Final staging00
Follow-up, 6 months1.80
Follow-up, 12 months2.10.6
End of study/early treatment termination0.60.6
SecondaryPercentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
Time frame:
Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies Over Time
percentage of participantsArm AArm B
Cycle 111.415.6
Cycle 27.018.2
Cycle 37.123.5
Cycle 47.014.7
Interim staging9.09.7
Cycle 512.510.2
Cycle 616.011.6
Cycle 723.810.9
Cycle 813.311.0
Final staging10.012.6
Follow-up, 6 months6.513.4
Follow-up, 12 months7.78.7
End of study/early treatment termination3.56.3
SecondarySummary of Observed Serum Rituximab Concentration
Time frame:
Pre-dose Cycle 1 to 8, interim staging, final staging, 6, 12 months follow-up, end of study (Up to 4 years)
Reported as:
Mean · microgram per milliter
Summary of Observed Serum Rituximab Concentration
microgram per milliterArm AArm B
Cycle 13355.9 ± 21600.95970.1 ± 9415.93
Cycle 225053.1 ± 19590.1724541.1 ± 18141.76
Cycle 362977.0 ± 30037.9846093.9 ± 31214.30
Cycle 487956.6 ± 40441.8459485.5 ± 29183.17
Interim staging117273.6 ± 52227.0677665.3 ± 29161.77
Cycle 5108030.9 ± 54335.0870387.3 ± 30256.48
Cycle 6100927.7 ± 49287.4298679.7 ± 40001.55
Cycle 795614.0 ± 45499.56117172.0 ± 44501.74
Cycle 8104873.0 ± 50346.69137048.1 ± 53669.39
Final staging86806.6 ± 43005.90120995.7 ± 58731.10
Follow-up, 6 months7802.9 ± 15672.578042.9 ± 12247.05
Follow-up, 12 months2380.1 ± 8494.061685.3 ± 6669.84
End of study/early treatment termination9302.0 ± 27234.889553.9 ± 30723.30

Adverse events

Collected over Randomization of first participant to clinical cutoff date (Up to 4 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A—126/371 (34%)318/371 (85.7%)
Arm B—116/369 (31.4%)317/369 (85.9%)
Most frequent serious events
Showing 10 of 153
Most frequent serious events
EventArm AArm B
Febrile NeutropeniaBlood and lymphatic system disorders31/37130/369
NeutropeniaBlood and lymphatic system disorders16/37113/369
PneumoniaInfections and infestations12/3719/369
Neutrophil count decreasedInvestigations11/37110/369
PyrexiaGeneral disorders10/3713/369
AnaemiaBlood and lymphatic system disorders3/3715/369
SepsisInfections and infestations3/3715/369
LeukopeniaBlood and lymphatic system disorders5/3711/369
AstheniaGeneral disorders4/3711/369
Lung InfectionInfections and infestations3/3713/369
Most frequent other events
Showing 10 of 29
Most frequent other events
EventArm AArm B
NauseaGastrointestinal disorders83/371102/369
FatigueGeneral disorders69/37191/369
AnaemiaBlood and lymphatic system disorders79/37168/369
NeutropeniaBlood and lymphatic system disorders51/37170/369
Neutrophil count decreasedInvestigations63/37169/369
ConstipationGastrointestinal disorders59/37160/369
AlopeciaSkin and subcutaneous tissue disorders60/37156/369
VomitingGastrointestinal disorders44/37157/369
PyrexiaGeneral disorders55/37148/369
DiarrhoeaGastrointestinal disorders45/37150/369

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm AArm BTotal
Mean58.2 ± 13.1859.4 ± 12.6458.8 ± 12.92
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female187180367
Male184189373
08

Study locations

246 sites
  • Buenos Aires, 1425, Argentina
  • Corrientes, 3400, Argentina
  • Santa Fé, 3000, Argentina
  • Canberra, Australian Capital Territory 2605, Australia
  • Camperdown, New South Wales 2050, Australia
  • Liverpool, New South Wales 2170, Australia
  • Randwick, New South Wales 2031, Australia
  • Brisbane, Queensland 4101, Australia
  • Adelaide, South Australia 5000, Australia
  • Hobart, Tasmania 7000, Australia
  • Geelong, Victoria 3220, Australia
  • Malvern, Victoria 3144, Australia
  • Melbourne, Victoria 3084, Australia
  • Wodonga, Victoria 3690, Australia
  • Nedlands, Western Australia 6009, Australia
  • Perth, Western Australia 6000, Australia
  • Krems, 3500, Austria
  • Linz, 4020, Austria
  • Salzburg, 5020, Austria
  • Steyr, 4400, Austria
  • Wien, 1140, Austria
  • Belo Horizonte, MG 30150-320, Brazil
  • Juiz de Fora, MG 36010-510, Brazil
  • Varginha, MG 37062-770, Brazil
  • Recife, PE 50070-550, Brazil
  • Curitiba, PR 81520-060, Brazil
  • Londrina, PR 86050-190, Brazil
  • Caxias do Sul, RS 95070-560, Brazil
  • Novo Hamburgo, RS 93510-250, Brazil
  • Santa Maria, RS 97015-373, Brazil
  • Santo Andre, SP 09060-650, Brazil
  • Sao Jose do Rio Preto, SP 15090-000, Brazil
  • Burnaby, British Columbia V5G 2X6, Canada
  • Vancouver, British Columbia V6Z 1Y6, Canada
  • Victoria, British Columbia V8R 6V5, Canada
  • Hamilton, Ontario L8V 5C2, Canada
  • Montreal, Quebec H1T 2M4, Canada
  • Santiago, 8380000, Chile
  • Santiago, 8420383, Chile
  • Viña del Mar, 2520612, Chile
  • Monteria, Colombia
  • Osijek, 31000, Croatia
  • Aalborg, 9000, Denmark
  • Holstebro, 7500, Denmark
  • Santiago de los Caballeros, 51000, Dominican Republic
  • Alexandria, 11737, Egypt
  • Cairo, 11562, Egypt
  • San Salvador, 1101, El Salvador
  • Aschaffenburg, 63739, Germany
  • Augsburg, 86150, Germany
  • Bamberg, 96049, Germany
  • Bayreuth, 95445, Germany
  • Berlin, 10559, Germany
  • Berlin, 10967, Germany
  • Berlin, 12351, Germany
  • Berlin, 13581, Germany
  • Bielefeld, 33604, Germany
  • Bielefeld, 33611, Germany
  • Bochum, 44787, Germany
  • Bochum, 44791, Germany
  • Bonn, 53127, Germany
  • Bottrop, 46236, Germany
  • Brandenburg, 14770, Germany
  • Bremen, 28177, Germany
  • Bremerhaven, 27568, Germany
  • Coesfeld, 48653, Germany
  • Darmstadt, 64283, Germany
  • Darmstadt, 64295, Germany
  • Dresden, 01127, Germany
  • Dresden, 01307, Germany
  • Düsseldorf, 40225, Germany
  • Eisenach, 99817, Germany
  • Essen, 45122, Germany
  • Essen, 45239, Germany
  • Frankfurt an der Oder, 15236, Germany
  • Frankfurt, 60389, Germany
  • Frankfurt, 60488, Germany
  • Frankfurt, 60596, Germany
  • Freiburg, 79110, Germany
  • Fürth, 90766, Germany
  • Georgsmarienhütte, 49124, Germany
  • Giessen, 35392, Germany
  • Giessen, Germany
  • Goslar, 38642, Germany
  • Gütersloh, 33332, Germany
  • Halle, 06110, Germany
  • Hamburg, 20246, Germany
  • Hamburg, 22081, Germany
  • Hamburg, 22457, Germany
  • Hamm, 59063, Germany
  • Hamm, 59071, Germany
  • Hanau, 63450, Germany
  • Hannover, 30171, Germany
  • Hannover, 30625, Germany
  • Herford, 32049, Germany
  • Jena, 07747, Germany
  • Kaiserslautern, 67655, Germany
  • Kassel, 34125, Germany
  • Köln, 50677, Germany
  • Leer, 26789, Germany

Showing the first 100 of 246 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, Re F, Trask P, Osborne S, Smith R, Grigg A. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017 Apr 1;28(4):836-842. doi: 10.1093/annonc/mdw685. PubMed 28031173 ↗
  • Theodore-Oklota C, Humphrey L, Wiesner C, Schnetzler G, Hudgens S, Campbell A. Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab. Patient Prefer Adherence. 2016 Sep 13;10:1767-1776. doi: 10.2147/PPA.S108489. eCollection 2016. PubMed 27695295 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2012
First posted
Nov 9, 2012
Start
Dec 2012
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Aug 29, 2016
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01724021
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 9, 2012
Start date
Dec 2012
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Aug 29, 2016
Last update
Jan 23, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion